Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 2.63% | 19.86% | 0.60% | 36.59% | 17.34% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.46% | -109.51% | -46.93% | -22.86% | -42.55% |
| Change in Net Operating Assets | 58.60% | -343.22% | 267.99% | -170.03% | -110.71% |
| Cash from Operations | -6.41% | -32.19% | 4.96% | 15.93% | -81.41% |
| Capital Expenditure | -- | -- | -- | 287.50% | -28.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 56.19% | -- | -- | -- | -- |
| Other Investing Activities | 63,424.58% | 1,119.65% | 154.06% | 98.54% | -- |
| Cash from Investing | 1,970.81% | 1,119.65% | 154.06% | 97.43% | 6,320.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 97.44% | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 481.82% | 97.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 333.55% | 8.47% | 111.91% | 85.14% | -50.93% |
